Interactive Modeling for Endless Utility of Pharmacogenetic Diagnostic Testing: Industriousness for Warfarin Remedial programme [Hemostasis and Thrombosis] <<>>
Written by Linder, M. W., Bon Homme, M., Reynolds, K. K., Gage, B. F., Eby, C., Silvestrov, N., Valdes, R. on September 29, 2009 – 12:00 am -Background: The relevance of pharmacogenetic results requires apparent correlations medium a prove evolve and an indicated well-defined advance of skirmish. We developed a computational decision-support instrumentality that combines patient-specific genotype and phenotype info to give critical dosage counsel. This tool, auspices of estimating quantitative and profane parameters associated with the metabolism- and concentration-dependent retort to warfarin, provides the vital patient-specific framework for interpreting global normalized correlation (INR) measurements.
Methods: We analyzed clinical information, plasma S-warfarin concentration, and CYP2C9 (cytochrome P450, kindred 2, subfamily C, polypeptide 9) and VKORC1 (vitamin K epoxide reductase complex, subunit 1) genotypes for 137 patients with steadfast INRs. Plasma S-warfarin concentrations were evaluated by VKORC1 genotype (–1639G>A). The steady-state plasma S-warfarin concentration was planned with CYP2C9 genotype–based margin rates and compared with genuine measurements.
Results: The plasma S-warfarin concentration required to takings the goal INR rejoinder is significantly (P < 0.05) associated with VKORC1 –1639G>A genotype (GG, 0.68 mg/L; AG, 0.48 mg/L; AA, 0.27 mg/L). Modeling of the plasma S-warfarin concentration according to CYP2C9 genotype predicted 58% of the diversification in quantified S-warfarin concentration: Leisurely [S-warfarin] = 0.67(Estimated [S-warfarin]) + 0.16 mg/L.
Conclusions: The objective spell of plasma S-warfarin concentration required to hand in a salubrious INR can be predicted from the VKORC1 genotype (pharmacodynamics), and the reformer changes in S-warfarin concentration after repeated habitually dosing can be predicted from the CYP2C9 genotype (pharmacokinetics). Combining the assiduity of multivariate equations for estimating the sustentation dispense with genotype-guided pharmacokinetics/pharmacodynamics modeling provides a sturdy agency for maximizing the value of CYP2C9 and VKORC1 evaluation results for unbroken devotion to long-suffering fret.
<<>>Tags: chemistry, clinic
Posted in Clinical Chemistry |
